Less than 30 days left to apply – don’t miss your chance
Ein Dokument
mehr
Storys zum Thema Krankheit
- Sprache:
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
MedHub-AI and Terumo partner to market AI-based FFR in Japan
Tel Aviv, Israel (ots/PRNewswire) - MedHub-AI, pioneer of AI-based FFR "AutocathFFR" software, today announced a distribution agreement with Terumo Corporation to bring AutocathFFR®, its groundbreaking AI-powered Software as a Medical Device (SaMD), to the Japanese market. This partnership marks a new era in coronary physiology assessment where AI technology delivers superior confidence, reproducibility, and clinical ...
mehrInnovative Molecules Completes Enrollment of Phase 1b Clinical Trial of IM-250
Munich (ots/PRNewswire) - Innovative Molecules GmbH Announces Completion of Phase 1b Enrollment for IM-250 in Genital Herpes Clinical Trial Innovative Molecules GmbH today announced the completion of enrollment in the Phase 1b portion of its ongoing Phase 1b/2a clinical trial evaluating IM-250, a next-generation helicase-primase inhibitor targeting herpes simplex virus ...
mehrBIAL Announces Oral Presentation at GBA1 Meeting 2025
Porto, Portugal (ots/PRNewswire) - BIAL, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced that it will give an oral presentation on its potential disease-modifying compound, BIA 28-6156, at the GBA1 Meeting 2025 being held June 5-7, 2025, in Montreal, Canada. The GBA1 Meeting 2025 is hosted by McGill University, focusing on all aspects of GBA1 research, from basic ...
mehrGrünenthal announces acquisition of the rights to Cialis® from Lilly in Mexico, Brazil & Colombia
Aachen, Germany (ots) - - Grünenthal announces that it agreed to acquire the commercial rights to Cialis® from Eli Lilly and Company in Mexico, Brazil and Colombia, further strengthening Grünenthal's footprint in Latin America. - As part of the acquisition, Grünenthal will transfer the manufacturing of Cialis® to its production site in Chile. - Since 2017, ...
mehrAI Meets Game Theory: How Language Models Perform in Human-Like Social Scenarios
mehr
NeutroFlow: Leading European Medical Consortium Awarded €2.5 Million Grant from EIC Transition Programme to Advance Predictive Biomarker Development for Immunotherapy Response
Heidelberg, Germany, Milan, Seville, Spain and Binyamina, Israel (ots/PRNewswire) - A European-led consortium comprising Heidelberg University Hospital (UKHD), the European Institute of Oncology (IEO), Virgen Macarena University Hospital, and OncoHost today announced that it has been awarded a €2.5 million grant ...
mehrTechnische Universität München
Identifying pathogens within minutes instead of days
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Mass spectrometry detects bacteria without time-consuming isolation and multiplication Identifying pathogens within minutes instead of days - Identification directly in tissue and stool samples - So far 232 medically important bacterial species detectable - Database must now be further expanded Speed and reliability are crucial in the diagnosis of diseases. Researchers at the ...
mehrEuropäischer Rechnungshof - European Court of Auditors
(Viimeinen muistutus) EU:n 650 miljardin euron elvytysvarat – Elpymis- ja palautumistukivälineen puutteista saadut keskeiset kokemukset (Tiedotustilaisuus, 6. toukokuuta)
Kutsu tiedotustilaisuuteen 6. toukokuuta 2025 EU:n 650 miljardin euron elvytysvarat – Elpymis- ja palautumistukivälineen puutteista saadut keskeiset kokemukset - Tiedotustilaisuus verkossa tiistaina 6. toukokuuta klo 10.00 ...
mehrEuropäischer Rechnungshof - European Court of Auditors
(Kutsu tiedotustilaisuuteen) EU:n 650 miljardin euron elvytysvarat – Elpymis- ja palautumistukivälineen puutteista saadut keskeiset kokemukset
Kutsu tiedotustilaisuuteen 6. toukokuuta 2025 EU:n 650 miljardin euron elvytysvarat – Elpymis- ja palautumistukivälineen puutteista saadut keskeiset kokemukset - Tiedotustilaisuus verkossa tiistaina 6. toukokuuta klo 10.00 ...
mehrAcousia Therapeutics Reaches 50% Patient Enrollment Milestone in Phase 2 PROHEAR Study
Tübingen, Germany (ots) - Acousia Therapeutics GmbH announced that it has successfully enrolled 50% of patients in its ongoing Phase 2 clinical trial, the PROHEAR Study, evaluating ACOU085 (INN: bimokalner) for the prevention of cisplatin-induced hearing loss in patients with testicular cancer undergoing chemotherapy. Cisplatin is a cornerstone in modern oncology and ...
mehrHelmholtz Launches Task Force to Strengthen Prevention Research
mehr
canSERV Open Call relaunches: Apply now for Free Access to Cutting-Edge Cancer Research Services
Ein DokumentmehrEngineering Smart Delivery for Gene Editors
mehrImmunity Pharma Presents New Data Supporting the Efficacy of IPL344 in ALS
Jerusalem (ots/PRNewswire) - - Results from phase 2a trial in ALS patients were published in Muscle and Nerve. - Statistically significant 58% to 64% slower ALSFRS-R progression rate in IPL344-treated patients compared to the matched PRO-ACT records. - NfL was reduced by 27% for patients treated for at least two months. - Unadjusted median survival for participants in ...
mehrSGLT2 HYPE: New EU-funded Project Aims to Transform Hypertension Treatment
mehrEuropäischer Rechnungshof - European Court of Auditors
(Pressinbjudan) Bidrog återhämtningsfonderna efter pandemin till bättre arbetsmarknader i EU-länderna?
Pressinbjudan till den 26 mars 2025 Bidrog återhämtningsfonderna efter pandemin till bättre arbetsmarknader i EU-länderna? - Presskonferens online onsdagen den 26 mars kl. 10.00 CET. - Offentliggörande samma dag kl. 17.00 ...
mehr- 3
Press Release STADA’s growth journey continues in 2024 - Significant increase in sales and profits - Growing ahead of the market
Ein Dokumentmehr
Apotex licenses exclusive Canadian rights to Qutenza® from Grünenthal
Aachen, Germany & Toronto, Canada, (ots) - Grünenthal, a global leader in pain management and related diseases, and Apotex Inc. ("Apotex"), the largest Canadian-based pharmaceutical company, announced today that they have entered into a strategic licensing agreement whereby Apotex will have the exclusive Canadian rights to Qutenza®, a topical, non-systemic, ...
mehrNew Knowledge Portal Adiposetissue.org Enhances Obesity and Metabolism Research with Centralized Data
mehrX4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe.
London (ots/PRNewswire) - Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 today that their Marketing Authorization Application (MAA) for mavorixafor for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis), a rare ...
mehrAncient Viral DNA Shapes Early Embryo Development
Over half of our genomes consists of thousands of remnants of ancient viral DNA, known as transposable elements, which are widespread across the tree of life. Once dismissed as the "dark side" of the genome, researchers at Helmholtz Munich and Ludwig-Maximilians-Universität (LMU) have now revealed their crucial role in early embryo development. Unanswered Questions About the Role of Ancient Viral DNA Transposable ...
mehrSCP-Nano: A New Technology to Visualize Nanocarriers in Cells and Tissues
mehrBosch Healthcare Solutions GmbH
Vivalytic Bacterial Meningitis by Bosch: PCR rapid test for medical emergencies
mehr
Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma
London (ots/PRNewswire) - Back to media releases Next media release Norgine today announced that it completed its marketing authorisation application filing to European Medicines Agency (EMA) for eflornithine in high-risk neuroblastoma (HRNB). This follows the submissions in April 2024, via Project Orbis, in ...
mehrRHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers
mehrAccord Healthcare is granted marketing authorisation for IMULDOSA®, ustekinumab biosimilar to Stelara®
London (ots/PRNewswire) - - Accord announces that the European Commission (EC has granted marketing authorisation for Imuldosa® (development code: DMB-3115), a biosimilar to Stelara®, indicated for a range of immune medicated inflammatory diseases. - The EC approval follows a positive opinion issued on 19 October ...
mehrMaria-Elena Torres-Padilla Honored With the Leibniz Prize 2025
mehrTechnische Universität München
Complex pancreatic tumor organoids as foundation for new treatment strategies
TECHNICAL UNIVERSITY OF MUNICH NEWS RELEASE Foundation for new cancer treatment strategies Organoids represent the complex cell landscape of pancreatic cancer - Tumors are composed of cancer cells with a variety of different characteristics. - This contributes significantly to the complexity of pancreatic cancer and makes the disease difficult to treat. - For the ...
mehrObrist Group Introduces Alternatives to PFAS and F-Gases
Obrist Group Introduces Alternatives to PFAS and F-Gases Natural Refrigerants Replacing Harmful Forever Chemicals in Cars Lindau/Germany, Lustenau/Austria – December 10 2024 – Per- and polyfluoroalkyl substances (PFAS) are recognized as highly hazardous, and the European Union is preparing to ban these toxic chemicals. The PFAS group also includes F-gases, such as hydrofluorocarbons, which are widely used in cooling ...
mehr
Vorherige12345678910Nächste